Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer
Abstract Background At least 50% of triple negative breast cancer (TNBC) overexpress the epidermal growth factor receptor, EGFR, which paved the way for clinical trials investigating its blockade. Outcomes remained dismal stemming from mechanisms of resistance particularly the nuclear cycling of EGF...
| Κύριοι συγγραφείς: | , , , |
|---|---|
| Μορφή: | Άρθρο |
| Γλώσσα: | English |
| Έκδοση: |
BMC
2020-04-01
|
| Σειρά: | Breast Cancer Research |
| Θέματα: | |
| Διαθέσιμο Online: | http://link.springer.com/article/10.1186/s13058-020-01270-1 |